EPHA3 and breast cancer: Interestingly, the EphA3 kinase inhibitor AWL-II-38.3, which is not able to modify the protein levels of EphA3 (Additional File 5), reduced the migratory (Fig. 6G-H) and invasive (F ig. 6I-J) capacities of MCF7/RAGE and T47D/RAGE cells, suggesting that the kinase-dependent EphA3 forward signaling may be implicated in the motility of RAGE-overexpressing BC cells.